Xcelience Expands Clinical Trial Supplies Manufacturing and Packaging

TAMPA, FL, USA (September 7, 2011) - Xcelience, a leader in early drug development, has expanded clinical trial supplies manufacturing and packaging capabilities to include four new pieces of equipment and a new fully-automated packaging line.

To complement existing expertise in matrix tablet delivery systems, Xcelience added a MG Futura (capsule-filling machine for powder and pellets), LCI Multi-granulator MG-55 (extruder), QJ-230T marumerizer (spheronizer), and wurster insert (bottom spray) to the existing Glatt GPCG-3 fluid bed processor. These new pieces enable production, coating and encapsulation of MUDF delivery systems.

"The new MG Futura is a great example of our continued commitment to add state-of-the-art technology that delivers real value to our clients," says Theodore Koontz, Director of Operations. "The MG Futura improves upon production times, increases overall capacity, and expands upon our existing capabilities for powders, pellets and powder micro-dosing for inhalation systems".

In addition, Xcelience has added a fully-automated packaging line (including ink-jet coding) for primary bottling of tablets and capsules. The new packaging line enhances the speed at which batches are packaged, shortens timelines, and enhances our ability to package larger batches of drug product.

About Xcelience LLC

Xcelience is a contract research organization providing formulation development, drug preformulation, analytical, and clinical supplies manufacturing to a global client base since 1997. The company is renowned for reliably expediting early development activities to speed potential drugs to clinical trials while applying stage-specific scientific knowledge and experience. Xcelience's unique corporate structure creates project teams that work intensively with each client, bringing an extension of their own organization into the Xcelience lab. For more detailed information about Xcelience, visit www.xcelience.com.

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.